Quantcast

Latest FOLFOX Stories

2008-10-23 12:00:26

Poniard Pharmaceuticals, a biopharmaceutical company, has announced positive incremental data from its randomized, controlled Phase II clinical trial of picoplatin in patients with metastatic colorectal cancer. The expanded and updated results continue to indicate that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin (FOLPI), is associated with less frequent and severe neurotoxicity than oxaliplatin given in combination with 5-fluorouracil and...

2008-10-22 06:00:08

SOUTH SAN FRANCISCO, Calif. and GENEVA, Oct. 22 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced positive incremental data from its randomized, controlled Phase 2 clinical trial of picoplatin in patients with metastatic colorectal cancer (CRC). The expanded and updated results continue to indicate that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin (FOLPI), is associated with...

2008-10-20 12:00:31

Genentech, a biotechnology company, has announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project that an ongoing Phase III study of Avastin plus chemotherapy in patients with early-stage colon cancer will continue as planned. The National Surgical Adjuvant Breast and Bowel Project's (NSABP) decision to continue the trial was based on a recommendation from an independent data monitoring committee (DMC) after a planned interim analysis. The study of...

2008-08-26 09:00:28

Aveo Pharmaceuticals has started another Phase Ib clinical study for its lead product candidate, the triple VEGF receptor inhibitor AV-951. This open-label, sequential dose escalation study will be conducted at cancer institutions in Europe and will evaluate AV-951 in combination with the Folfox6 chemotherapy regimen in patients with advanced colorectal cancer and other gastrointestinal cancers. This Phase Ib combination therapy trial is designed to determine the safety, tolerability and...

2008-06-18 12:01:00

Saladax Biomedical has received CE mark registration in the EU for its 5-FU Personalized Chemotherapy Management assay on the Olympus AU400 clinical chemistry analyzer. For European oncologists who prescribe 5-fluorouracil (5-FU) continuous infusion regimens alone or in combination (eg Folfox and Folfiri) for colorectal, stomach, breast, and pancreatic cancers, this simple, evidence-based blood test will show patients's actual plasma 5-FU levels for individualized dosing. Recently,...

2007-01-23 15:00:58

Preliminary results show the combination of Xeloda plus Eloxatin, known as XELOX, to be equivalent to standard FOLFOX-4 chemotherapy treatment in terms of overall survival in first-line metastatic colorectal cancer patients. Given its dosing convenience advantage, XELOX has the potential to be a first-line treatment, provided it can be demonstrated as cost-effective. The 2,034 metastatic colorectal cancer patient study was originally designed to compare first-line XELOX (Roche/Chugai's...

2004-11-29 18:00:12

PARIS, Nov. 29 /PRNewswire-FirstCall/ -- Patients who received ELOXATIN-based chemotherapy (FOLFOX4) plus bevacizumab (Avastin(TM)) showed a statistically significant improvement in overall survival in a large randomized clinical study sponsored by the National Cancer Institute and conducted by the Eastern Cooperative Oncology Group (ECOG). Preliminary results announced today are showing a 26% reduction in the risk of death for patients receiving FOLFOX4 plus bevacizumab (Avastin(TM))...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.